What happened with AIM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
AIM ImmunoTech is a drug developer whose main focus is testing Ampligen as a treatment for late-stage pancreatic cancer. It has not established a business with material product revenue. Patients participating in its Ampligen Cost Recovery Program provide limited revenue, which varies with participation; financing, rather than drug sales, primarily funds its operations and clinical studies. The company says it needs additional funding to continue that work.
Ampligen is not FDA-approved and cannot be commercially marketed in the United States. Argentina has approved it for severe chronic fatigue syndrome, but AIM says treatment costs have made its use there unaffordable for now. Its other product, Alferon N Injection, has approval for certain uses in the United States and Argentina, but sales have stopped because finished inventory is unavailable, and production is on hold.
Turning Ampligen into a commercial business depends on clinical development, regulatory approval and reliable manufacturing. AIM uses outside manufacturers, and it must complete and fund validation of the polymer-production process with Sterling Pharma Solutions before it can manufacture more polymer and Ampligen.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
AIM’s prospects hinge on financing and successful pancreatic-cancer trials, while further Ampligen production depends on completing process validation with Sterling Pharma Solutions.
Revolution Medicines’ daraxonrasib competes with AIM’s Ampligen for the advanced pancreatic-cancer treatment opportunity, despite working differently. Its progress in pancreatic cancer is therefore worth watching for the competition facing AIM’s lead drug program.
AIM’s DURIPANC trial pairs Ampligen with AstraZeneca’s marketed cancer drug Imfinzi, directly tying AIM’s development work to that drug. Watch the combination’s results in metastatic pancreatic-cancer patients whose disease remained stable after FOLFIRINOX treatment.
AIM is relying on Thermo Fisher Scientific’s PPD clinical research business to design its anticipated Phase 3 pancreatic-cancer trial, under a March 2026 agreement. Thermo Fisher sells research products and services to drug developers; here, the trial design is the work to watch for AIM’s lead development program.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher’s report will show how its PPD clinical research business is doing, the business AIM is relying on to design its anticipated Phase 3 pancreatic-cancer trial.
Watch the performance of Thermo Fisher’s clinical research business and any reported progress on the trial-design work it is undertaking. A steady business and advancing design work would support AIM’s preparation for a key trial; pressure on the business or stalled work could delay AIM’s pancreatic-cancer program.
AstraZeneca PLC earningsAZN
AstraZeneca’s report will show how Imfinzi is doing commercially; AIM pairs the drug with Ampligen in its DURIPANC pancreatic-cancer trial.
Watch AstraZeneca’s discussion of Imfinzi and whether the treatment setting studied by DURIPANC remains commercially and clinically relevant. A steady Imfinzi business supports the marketed-drug foundation of the combination; weakness would add uncertainty about its commercial prospects, but cannot show whether Ampligen adds benefit—that depends on AIM’s trial results.
Revolution Medicines, Inc. earningsRVMD
Revolution Medicines’ report will show progress on its pancreatic-cancer drug candidate daraxonrasib, which competes with AIM’s Ampligen for the advanced pancreatic-cancer treatment opportunity.
Watch Revolution Medicines’ account of daraxonrasib’s progress in pancreatic cancer. Continued progress would mean AIM’s Ampligen faces a rival program advancing in the same treatment opportunity; a setback could ease that competitive pressure, but would not prove Ampligen works—AIM’s own clinical data must answer that.
AIM ImmunoTech Inc. earningsThis company
AIM ImmunoTech’s report will show how its lead Ampligen pancreatic-cancer program is progressing and whether the company’s cash can support further clinical development.
Read progress in the Ampligen pancreatic-cancer program alongside cash used in operations. Progress with cash use contained would show AIM can advance its key development work within limited resources; a stalled program or faster cash use would show that financing pressure could restrict trial progress and threaten continued operations.
